The ocular drug delivery system market is forecast to surpass US$ 16,159.9 million in 2023, according to Future Market Insights. Due to the rising cases of ophthalmic diseases, the focus on advanced treatment is rising, enabling a surge in ocular drug delivery systems demand at a CAGR of 6.9% between 2023 and 2033.
The sales of ocular drug delivery systems are expected to total US$ 31,410.2 million by 2033. The demand for particulate drug delivery systems is anticipated to be the highest. It is expected to account for over 70% of the global market in 2023.
Drivers:
Restraints:
Opportunities:
Trends:
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to Future Market Insights (FMI), the sales of ocular drug delivery systems have grown at a 6.2% CAGR between 2018 to 2022. Ocular drug delivery systems are platforms designed for dispensing drug, biologic, biopharmaceutical, and botanical therapeutics for treating macular degeneration, glaucoma, presbyopia, allergy, anti-viral, dry eye, anti-infective, and anti-inflammatory indications.
To overcome ocular drug delivery barriers and improve bioavailability, various conventional and novel drug delivery systems have been developed, such as ointments, emulsions, suspensions, aqueous gels, nano micelles, liposomes, dendrimers, implants, contact lenses, nanoparticles, Nano suspensions, microneedles, and in situ thermosensitive gels for the earlier mention ocular diseases.
Market players' key focus is developing tools to improve the efficacy of spatiotemporal drug administration. Research studies on novel drug delivery treatments for posterior eye therapy using implantable devices and micro- and nanoparticles are expected to increase the efficacy of advanced ocular drug delivery technologies. Companies specializing in ocular drug delivery technologies are constantly increasing their research and development expenditures. This trend is likely to continue during the forecast period.
Advanced ocular drug delivery technologies require Huge expenditure during the developmental stages. With the rise in new entrants, the overall research and development expenses are projected to rise exponentially, along with collaborations and licensing agreements with several research institutes.
Future Market Insights projects the global ocular drug delivery system market to rise at 6.9% CAGR between 2023 and 2033.
With pharmaceutical spending consistently rising in developed countries, the demand for ocular drug delivery systems is expected to increase. Emerging markets, especially large markets such as India and China, have significant untapped potential. With the rise in disposable income, these nations continue spending on innovative technologies for better treatment modalities.
The low bioavailability of active drug ingredients administered in the eye by conventional topical routes such as solutions & ointments is usually a major obstacle to overcome. This is a result of effective multiple physiological barriers for drug entry. The administration of drugs to the posterior segment of the ocular tissue is inhibited by the same factors that account for poor ocular bioavailability.
To enhance the bioavailability of ocular therapeutics, substantial efforts are directed toward advanced drug delivery technologies for ophthalmic administration.
Studies exhibit that micellar formulations can improve the bioavailability of the drugs in ocular tissues, suggesting enhanced therapeutic outcomes. Also, derivatizing active pharmaceutical ingredients (API) and enhancing the ocular drug bioavailability using an emulsion as a carrier system is a phenomenal concept followed by key players in this space.
Key players are focusing on developing new drug delivery techniques in the ophthalmic market to increase drug penetration through corneal & other ocular barriers in the anterior portion of the eye.
Principal Consultant
In the case of advanced ocular drug delivery systems, insertion techniques are difficult, and expulsion of shields occurs, causing the occasional accidental loss of the drug. Thus, using penetration enhancers to improve corneal drug transport.
The use of ocular penetration enhancers like para-cellular pathways and phase transition systems is likely to increase the opportunity for the ocular drug delivery system market. Moreover, the protective barrier mechanisms of the human eye arrest the efficiency of drug delivery, providing an opportunity to develop mechanisms to bypass these barriers during drug administration.
Several ongoing clinical trials are executed to understand the efficacy of bypass mechanisms, which are predicted to efficiently address the problem of ocular drug bioavailability.
Ocular inserts and implants provide advantages such as high corneal penetration, greater dissolution area, and sustained release of medication. However, the foreign body sensation in the eye due to the solidity of the implants leads to discomfort accompanied by irritation, drug dilution, and excessive lachrymation.
The nasolacrimal drainage through lacrimal canaliculi refers to the systemic absorption of the drug across the gastrointestinal tract or the nasal mucosa, which leads to a loss in its overall volume. This reduction in the volume of drugs and rare cases of allergic reactions in the lacrimal system after the drug passage are some of the factors restraining the efficiency of ocular drug delivery.
Also, the reduction in patient compliance and adherence to novel ocular therapies due to high cost and associated complexities are anticipated to act as barriers to advanced drug delivery technologies in the global ocular drug delivery technologies market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Region | Market Share in 2022 |
|---|---|
| United States | 86.7% |
| Germany | 17.2% |
| Japan | 52.4% |
The United States holds over 86.7% share in North America's ocular drug delivery system market. In the United States, growth is led by research collaboration and license agreements for clinical products. Rising technological advancements allow manufacturers to deliver therapeutic drugs to targeted ocular tissues in sustained form and provide protection from inflammatory conditions.
Expansion strategies are implemented by some of the leading manufacturers in the country to strengthen their product portfolio. For instance, in October 2020, Ocular Therapeutix™ and AffaMed Therapeutics announced a license agreement and collaboration for DEXTENZA® and OTX-TIC in Asia.
| Region | United Kingdom |
|---|---|
| CAGR (2023 to 2033) | 5.2% |
The United Kingdom market is anticipated to exhibit a 5.2% CAGR throughout the forecast period. Common clinical developments, the demand for extensive product portfolios, and improvements in drug development pipelines and production capacities are key factors speeding growth in the United Kingdom market.
Some market players focus on acquisitions to expand their portfolio for over-the-counter drugs in the United Kingdom market.
Germany is likely to hold a 17.2% share in the ocular drug delivery system industry through 2033. Regulatory guidelines are relatively strict in Germany. As a result, achieving drug approvals is a hard process. Germany is the second leading market in Europe. Some of the leading players are eying to expand their footprint in Germany.
For instance, Vision Ophthalmology Group GmbH is acquired by AddLife AB, an independent operator in Life Science that offers high-quality products and services within a wide variety of therapeutic areas to both private and public sectors across Europe.
The Japanese market is likely to account for more than 52.4% of the sales registered in East Asia in 2023. Increasing healthcare spending has improved healthcare quality while boosting the demand for pharmaceutical products in Japan.
According to International Trade Administration, the overall Japanese market for prescription, as well as over-the-counter drugs, totaled US$ 105 million in 2019. The government of Japan provides healthcare spending for around 40% of people living in the country via national insurance schemes. These policies are likely to continue favoring the expansion of the market in Japan.
Japan’s pharmaceutical sector is anticipated to showcase moderate growth in the coming years due to high pricing. Despite this, it is projected to remain a favorable destination for international biopharmaceutical companies for drug development and innovative therapies.
With a dominant market share of 68.05% in 2023, particulate drug delivery systems revolutionize the ocular drug delivery landscape. These systems utilize microscopic particles to transport drugs to the target site within the eye, ensuring precise and controlled release. The unique factor that sets particulate drug delivery systems apart is their ability to enhance bioavailability and prolong drug residence time, maximizing therapeutic efficacy. Their versatility enables customization of particle size, surface properties, and drug loading capacity, enabling tailored solutions for diverse ocular conditions. The growing adoption of particulate drug delivery systems can be attributed to their potential for sustained and targeted drug delivery, improving patient outcomes and optimized treatment regimens.
Capturing a significant market share of 62.23% in 2023, ophthalmic solutions dominate the dosage form segment of the ocular drug delivery system industry. Ophthalmic solutions, consisting of drug substances dissolved or dispersed in a liquid vehicle, offer several advantages for ocular administration. Their unique factor lies in their ease of application and rapid drug absorption, ensuring quick therapeutic effects. Ophthalmic solutions provide convenience and patient compliance due to their user-friendly nature, allowing precise installation and avoiding discomfort.
In the distribution channel segment, hospital pharmacies hold a dominant market share of 44.6% in 2023. Hospital pharmacies play a crucial role in the supply chain of ocular drug delivery systems, ensuring the availability of specialized medications and facilitating efficient distribution to healthcare providers. Their unique factor lies in their ability to provide comprehensive pharmaceutical services within the hospital setting, including storage, dispensing, and patient counseling. Hospital pharmacies offer a controlled environment for handling and storing ocular drug delivery systems, maintaining product quality and safety.
The ocular drug delivery system industry is characterized by intense competition, driven by innovation and the quest to offer superior products and solutions. Key players in the market continuously strive to stay at the forefront of advancements, aiming to address unmet needs and gain a competitive edge. These industry leaders invest significant resources in research and development to develop novel drug delivery technologies, forge strategic partnerships, and expand their product portfolios. Their focus on enhancing drug efficacy, improving patient compliance, and ensuring safety set them apart in the competitive landscape.
Despite their prominence, key players in the ocular drug delivery system industry face various challenges. The complex formulation requirements specific to ocular administration pose significant hurdles. Ensuring drug safety, efficacy, and bioavailability within the delicate ocular tissues requires meticulous development processes and rigorous testing.
Strategic partnerships and collaborations with pharmaceutical companies, research institutions, and healthcare providers can provide access to resources, expertise, and market networks. Exploring untapped markets and expanding the global presence of ocular drug delivery systems also presents avenues for growth and differentiation.
Scaling Strategies for Manufacturers/Service Providers in the Market
| Attribute | Details |
|---|---|
| Ocular Drug Delivery System Market Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Ocular Drug Delivery System Market Analysis | US$ million for Value/ Units in a million for volume |
| Ocular Drug Delivery System Market - Key Countries Covered | United States, Canada, Germany, United Kingdom, France, Italy, Spain, Poland, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Turkey, South Africa |
| Ocular Drug Delivery System Market - Key Segments Covered | Technology, Dosage Form, Distribution Channel, and Region |
| Ocular Drug Delivery System Market - Key Companies Profiled |
|
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The market is estimated to secure a valuation of US$ 16,159.9 million in 2023.
The ocular drug delivery system market is estimated to 6.9%.
The leading market players are Graybug Vision Inc., Allergan Plc., and Ocular Therapeutix, Inc.
The United Kingdom market is expected to surge at a CAGR of 7.2% through 2033.
Particulate is estimated to remain preferred in the market.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Technology
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Technology, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Technology, 2023 to 2033
5.3.1. Implantable Ocular Drug Delivery Systems
5.3.2. Particulate Drug Delivery Systems
5.3.3. Nano-Particle Drug Delivery System
5.4. Y-o-Y Growth Trend Analysis By Technology, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Technology, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Dosage Form
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Dosage Form, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Dosage Form, 2023 to 2033
6.3.1. Ophthalmic Solution
6.3.2. Ophthalmic Suspension
6.3.3. Ophthalmic Emulsion
6.3.4. Ophthalmic Gels
6.3.5. Ophthalmic Ointments
6.4. Y-o-Y Growth Trend Analysis By Dosage Form, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Dosage Form, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Drug Store
7.3.4. Mail Order Pharmacies
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia
8.3.5. East Asia
8.3.6. Oceania
8.3.7. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Technology
9.2.3. By Dosage Form
9.2.4. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Technology
9.3.3. By Dosage Form
9.3.4. By Distribution Channel
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Technology
10.2.3. By Dosage Form
10.2.4. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Technology
10.3.3. By Dosage Form
10.3.4. By Distribution Channel
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. UK
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Technology
11.2.3. By Dosage Form
11.2.4. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Technology
11.3.3. By Dosage Form
11.3.4. By Distribution Channel
11.4. Key Takeaways
12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Rest of South Asia
12.2.2. By Technology
12.2.3. By Dosage Form
12.2.4. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Technology
12.3.3. By Dosage Form
12.3.4. By Distribution Channel
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Technology
13.2.3. By Dosage Form
13.2.4. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Technology
13.3.3. By Dosage Form
13.3.4. By Distribution Channel
13.4. Key Takeaways
14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. Australia
14.2.1.2. New Zealand
14.2.2. By Technology
14.2.3. By Dosage Form
14.2.4. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Technology
14.3.3. By Dosage Form
14.3.4. By Distribution Channel
14.4. Key Takeaways
15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Technology
15.2.3. By Dosage Form
15.2.4. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Technology
15.3.3. By Dosage Form
15.3.4. By Distribution Channel
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Technology
16.1.2.2. By Dosage Form
16.1.2.3. By Distribution Channel
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Technology
16.2.2.2. By Dosage Form
16.2.2.3. By Distribution Channel
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Technology
16.3.2.2. By Dosage Form
16.3.2.3. By Distribution Channel
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Technology
16.4.2.2. By Dosage Form
16.4.2.3. By Distribution Channel
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Technology
16.5.2.2. By Dosage Form
16.5.2.3. By Distribution Channel
16.6. UK
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Technology
16.6.2.2. By Dosage Form
16.6.2.3. By Distribution Channel
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Technology
16.7.2.2. By Dosage Form
16.7.2.3. By Distribution Channel
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Technology
16.8.2.2. By Dosage Form
16.8.2.3. By Distribution Channel
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Technology
16.9.2.2. By Dosage Form
16.9.2.3. By Distribution Channel
16.10. India
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Technology
16.10.2.2. By Dosage Form
16.10.2.3. By Distribution Channel
16.11. Malaysia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Technology
16.11.2.2. By Dosage Form
16.11.2.3. By Distribution Channel
16.12. Singapore
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Technology
16.12.2.2. By Dosage Form
16.12.2.3. By Distribution Channel
16.13. Thailand
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Technology
16.13.2.2. By Dosage Form
16.13.2.3. By Distribution Channel
16.14. China
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Technology
16.14.2.2. By Dosage Form
16.14.2.3. By Distribution Channel
16.15. Japan
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Technology
16.15.2.2. By Dosage Form
16.15.2.3. By Distribution Channel
16.16. South Korea
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Technology
16.16.2.2. By Dosage Form
16.16.2.3. By Distribution Channel
16.17. Australia
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Technology
16.17.2.2. By Dosage Form
16.17.2.3. By Distribution Channel
16.18. New Zealand
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Technology
16.18.2.2. By Dosage Form
16.18.2.3. By Distribution Channel
16.19. GCC Countries
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Technology
16.19.2.2. By Dosage Form
16.19.2.3. By Distribution Channel
16.20. South Africa
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Technology
16.20.2.2. By Dosage Form
16.20.2.3. By Distribution Channel
16.21. Israel
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Technology
16.21.2.2. By Dosage Form
16.21.2.3. By Distribution Channel
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Technology
17.3.3. By Dosage Form
17.3.4. By Distribution Channel
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Graybug Vision Inc.
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Allergan Plc.
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Ocular Therapeutix, Inc.
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. Alimera Sciences
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. pSivida,
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. Santen Pharmaceutical Co., Ltd
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Taiwan Liposome Company Ltd.
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. Envisia Therapeutics
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Eyegate Pharma
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. Valeant Pharmaceuticals International, Inc
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
18.1.11. Vision Ophthalmology Group GmbH
18.1.11.1. Overview
18.1.11.2. Product Portfolio
18.1.11.3. Profitability by Market Segments
18.1.11.4. Sales Footprint
18.1.11.5. Strategy Overview
18.1.11.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports
Ocular Drug Delivery System Market
